ArticleBMC gastroenterology2025
Clinical application and effectiveness analysis of modified Asia-Pacific colorectal cancer screening score combined with fecal occult blood test for colorectal cancer screening in asymptomatic population.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the value of the modified Asia-Pacific colorectal cancer screening (APCS) scoring system combined with fecal occult blood test (FOBT) for colorectal cancer (CRC) screening in asymptomatic population of Wannan region.
methodsWe prospectively collected and investigated asymptomatic individuals attending Yijishan Hospital (the first affiliated hospital of Wannan Medical College) from January 1, 2021 to December 31, 2022. All enrolled patients received modified APCS scores and FOBT before colonoscopy. We used receiver operating characteristic (ROC) curves to estimate the screening value of the modified APCS score combined with FOBT. We also retrospectively collected patients with stage T1 CRC to explore the independent risk factors for lymph node metastasis (LNM) of CRC.
results513 participants were finally included in the study. The combined detection of modified APCS score and FOBT can be divided into 5 groups [modified APCS high risk &FOBT + (T1 group), modified APCS high risk &FOBT- (T2 group), modified APCS medium risk &FOBT + (T3 group), modified APCS medium risk &FOBT- (T4 group), and modified APCS low risk &FOBT- (T5 group)], the detection rates of CRC were 9.09%, 1.67%, 5.77%, 0.92% and 0%, respectively. The detection rate of advanced adenoma was 25.76%, 35.00%, 21.15%, 2.75% and 1.96%, respectively. The detection rate of CRC in T1 group was 9.88 times that in T4 group, and the detection rate of advanced adenoma was 9.36 times that in T4 group. The high-risk group and positive rate of modified APCS were indicators for further colonoscopy. Tumor gross morphology, tumor differentiation degree, and nerve infiltration were independent risk factors for T1 CRC LNM.
conclusionsThe combination of modified APCS score and FOBT test has important clinical application value in the preliminary screening of colorectal tumors in asymptomatic population. For selected T1 CRC patients, if the lesion is ulcerative and the pathology indicates low differentiation, endoscopic submucosal dissection (ESD) treatment should be carefully selected to prevent the risk of LNM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.